Ophthotech Corp is a biopharmaceutical company specializing in the development of novel therapeutics to treat diseases of the back of the eye with a focus on developing therapeutics for age-related macular degeneration.


Updates from The Motley Fool

Latest updates on Ophthotech from Fool.com.
Fovista Flops: What's Next?

Ophthotech's future is in jeopardy following a high-profile phase 3 failure.



Stock Performance

View Interactive OPHT Charts
Sponsored by

Key Data Points

Primary metrics and data points about Ophthotech.
Current Price: $1.40
Prev Close: $1.43
Open: $1.43
Bid: $1.37
Ask: $1.85
Day's Range: $1.40 - $1.48
52wk Range: $1.02 - $4.50
Volume: 232,172
Avg Vol 241,696
Market Cap: $58M
P/E (ttm): -1.02
EPS (ttm): -$1.40
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Ophthotech.
CAPS Rating 4 out of 5
 
50 Outperform
3 Underperform
CAPS All Stars
 
15 Outperform
1 Underperform

How do you think Ophthotech will perform against the market?



You pick for Ophthotech is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


Business Summary

Industry, sector and description for Ophthotech.

Ophthotech Corp is a biopharmaceutical company specializing in the development of novel therapeutics to treat diseases of the back of the eye with a focus on developing therapeutics for age-related macular degeneration.

  • Exchange: NASDAQ